Citizen Health key facts
- Developer of an AI-powered patient data platform designed to optimize rare disease care management and research advancement.
- Citizen Health’s last known valuation is $156.5M (Aug 2025).
- It has raised $44.5M; the latest was Later Stage VC ($30.0M) in Aug 2025.
- Notable investors include 8VC, Headline, Transformation Capital, Chan Zuckerberg Initiative, Wavemaker360.
- Status: Acquired/Merged (Operating Subsidiary).
Who backs Citizen Health
5- ·Watch Citizen Health: the Monday email on marks, rounds and moves
Citizen Health funding rounds
No funding rounds for Citizen Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Citizen Health valuation
Citizen Health's last known valuation is $157 million, from Aug 2025. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Citizen Health investors
5 investors are on record for Citizen Health, including 8VC, Headline, Transformation Capital and Chan Zuckerberg Initiative.
About Citizen Health
Developer of an AI-powered patient data platform designed to optimize rare disease care management and research advancement. The company's platform aggregates and unifies comprehensive, longitudinal medical records, including clinical notes, imaging, genetics, and outcomes data, with regulatory-grade compliance, provides secure patient-controlled data access, supports real-time question answering, enabling rare disease patients and their families to efficiently understand and share medical history, improving access to tailored care insights and research opportunities.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2017
- Employees
- 19
- Website
- citizen.health/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Citizen Health’s last known valuation, Aug 2025. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.